Cigna (CI)
Health Care · $77.9B market cap · SEC CIK 0001739940
ahead of 53% of the S&P 500 · #29 of 59 in Health Care
Next reports on Feb 3, 2027, after the close, with analysts expecting $7.49 in earnings per share.
52-week range $255.53 to $318.05. 5% below its 52-week high and 19% above its low.
The case for CI
- Reasonably priced for its growth: 13.0× earnings, where 6% a year of growth plus a 1.7% dividend would justify about 19×.
- Has compounded revenue at 11.4% a year over five years.
- Moves less than the market (beta 0.19).
- Pays a modest 1.7% dividend.
- Price/sales of 0.3× is lower than 93% of Health Care companies.
The case against
- Net margin of 2.1% leaves very little room for error.
- Current liabilities exceed current assets (ratio 0.84).
What the score is made of
Each factor is half a curve over reported figures and half a rank among the other Health Care companies (momentum is judged against fixed thresholds only), and the five are blended by weight. The score is where that blend places it in the S&P 500. It describes the last filing and the current price. It is not a forecast.
| Valuewhat you pay for the earnings and cash, against the growth you get | 73 |
|---|---|
| Growthhow fast revenue and earnings are moving, this year and over five | 46 |
| Profitabilityhow much of the revenue becomes profit, and how much of that is cash | 33 |
| Momentumhow the price has behaved lately | 67 |
| Stabilityhow violently it moves, what it owes and what it pays you | 75 |
- Capital spending is missing from its filings, so free cash flow cannot be worked out. Operating cash flow stands in for the cash test, against a stricter bar.
- Each factor except momentum is half fixed thresholds, half rank among the 59 Health Care companies.
The financials
Revenue growth
Is the business growing? Slowly
| Last 12 months | +6.8% |
|---|---|
| Over 5 years | +11.4% a year |
| FY2025 revenue | $275B (+11%) |
Free cash flow
Is it generating real cash? Can't tell: no capital spending in its filings
| FY2025 operating cash flow | $9.6B |
|---|---|
| Of profit, before capital spending | 161% |
Its filings do not give capital spending, so free cash flow cannot be worked out. Operating cash flow, which is before that spending, is shown instead, and the score judges it against a stricter bar.
Profit margins
Is profitability improving? Holding steady
| Gross margin | 9% |
|---|---|
| Operating margin | 3% |
| Net margin, FY24 → FY25 → now | 1.4% → 2.2% → 2.1% |
Debt vs. cash
Is the balance sheet healthy? Mostly, with some debt to carry
| Cash | $7.7B |
|---|---|
| Long-term debt | $30.9B |
| Net debt | $23.2B |
| Years to repay | 3.2 yrs |
Valuation
Is the stock price reasonable? Yes, it looks cheap
| P/E | 13.0× |
|---|---|
| Fair P/E for its growth | 19× |
| P/FCF | n/a |
| Forward P/E | 9.1× |
| EV / EBITDA | 8.9× |
At 13.0× earnings it trades below the 19× that 6% a year of growth plus a 1.7% dividend would justify.
The financials, five years deep
Pulled from Cigna's XBRL filings on SEC EDGAR. Italic rows are worked out from the others.
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue growth | |||||
| Revenue | $275B | $247B | $195B | $181B | $174B |
| Change on the year | +11% | +27% | +8% | +4% | — |
| Profit margins | |||||
| Operating margin | 3.3% | 3.8% | 4.4% | 4.7% | 4.6% |
| Net margin | 2.2% | 1.4% | 2.6% | 3.8% | 3.1% |
| Debt vs. cash | |||||
| Cash | $7.7B | $7.5B | $7.8B | $5.9B | $5.1B |
| Long-term debt | $30.9B | $28.9B | $28.2B | $28.1B | $31.1B |
| Net cash (debt) | −$23.2B | −$21.4B | −$20.3B | −$22.2B | −$26.0B |
What Cigna says it does
OVERVIEW The Cigna Group ® , together with its subsidiaries (either individually or collectively referred to as the "Company," "we," "us" or "our"), is a global health company. Our Focused Mission The Cigna Group is a global health company committed to creating a better future for every individual and every community. Powered by our dedicated people and valued brands, we advance our mission to improve the health and vitality of those we serve by staying grounded in the needs of our customers and patients - delivering a personalized, transparent and affordable health care experience. We focus on leading the way to partner and innovate solutions for better health. At The Cigna Group our global workforce of approximately 67,700 colleagues strives to fulfill our mission to improve the health and vitality of more than 185 million customer relationships in more than 30 markets and jurisdictions (as of December 31, 2025). We play an important…
Risk factors CI lists in its 10-K
- Changes in drug pricing or industry pricing benchmarks could materially impact our financial performance
- In managing medical practices and operating pharmacies, onsite clinics and other types of medical facilities, we may be subject to additional liability that could result in significant time and expense
- Legal, Regulatory and Public Policy Risks Arising from Our Business
- If we fail to comply with applicable privacy, security and data laws, regulations and standards, our business and reputation could be materially adversely affected
- We face risks related to litigation, regulatory audits and investigations
- Extensive health care regulation and enforcement, including fraud, waste and abuse laws, could increase our compliance costs, restrict our operations and expose us to significant liability
- Our business depends on our ability to effectively invest in, improve and properly maintain the uninterrupted operation, availability and data integrity of our information technology and other business systems
- Our use of artificial intelligence and machine learning present regulatory and legal challenges that could negatively affect our business and our reputation
- We are dependent on the success of our relationships with third parties for various services and functions
- A significant disruption in service within our operations or among our key suppliers or other third parties could materially adversely affect our business, liquidity and results of operations
- We face political, legal, operational, regulatory, economic and other risks in connection with our international operations
- Future performance of our business will depend on our ability to execute our strategic and operational initiatives effectively
- Economic and market conditions affect the value of our financial instruments and the value of particular assets and liabilities, investment income, and interest expense
- Significant stock market or interest rate declines could result in unfunded pension obligations, resulting in the need for additional plan funding by us and increased pension expenses
- Unfavorable developments in economic conditions may adversely affect our business, results of operations and financial condition
- We are subject to the credit risk of our reinsurers